Today, Genovis has acquired the patent rights to a unique DNA polymerase developed by researchers at Uppsala University. The enzyme has potential applications in research, diagnostics and forensics. 

As a leading developer of enzymes for the life science industry, Genovis has acquired the rights to a new enzyme developed by researchers at Uppsala University, led by Professor Ola Söderberg.

“We have developed a new type of DNA polymerase with properties that could not have arisen naturally. This laboratory-created DNA polymerase opens up fantastic opportunities for biotechnology and medical research”, says Ola Söderberg

The acquisition of the rights gives Genovis exclusive rights to develop and commercialize products based on the DNA polymerase. With the acquisition of the IP rights, Genovis will expand its customer offering to include enzymes in genomics.

“We are excited to have the opportunity to acquire the rights to a unique enzyme with potential uses in several applications within the life science field, from research to diagnostics and forensics. The acquisition follows our strategy to commercialize academic research into high-value products and broaden our offerings”, says Fredrik Olsson, CEO of Genovis.

In preparation for the commercialization of the enzyme, Genovis will initiate collaborations with partners as part of the continued product development.

For more information, please contact: Fredrik Olsson, CEO, Genovis AB Tel: +46 (0)70-276 46 56 [email protected]

Genovis’ business concept is to apply its knowledge and customer driven innovation to design and provide tools for the development of the drugs of the future. Today Genovis sells several enzyme products known as SmartEnzymes™ all over the world in innovative product formats that facilitate development and quality control of biological drugs.

The Group consists of Genovis AB and the wholly owned subsidiary Genovis Inc. (US). Genovis shares are listed on Nasdaq First North Growth Market and Erik Penser Bank is the Company’s Certified Adviser, [email protected], tel: +46 (0)8-463 83 00.

This is a translation of the Swedish original. In the event of any discrepancy between this translation and the Swedish original, the Swedish version shall prevail.